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Introduction {#jah32144-sec-0004}
============

In 2013, American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines based on high‐quality evidence were published.[1](#jah32144-bib-0001){ref-type="ref"} These guidelines replaced the previous cholesterol treatment guidelines: the third report of the national cholesterol education program/adult cholesterol treatment panel III (NCEP/ATP III).[2](#jah32144-bib-0002){ref-type="ref"} Applying data from the National Health and Nutrition Examination Surveys, researchers suggested that the new 2013 ACC/AHA guidelines for the management of cholesterol could potentially increase the number of statin‐therapy eligible US adults by 12.8 million.[3](#jah32144-bib-0003){ref-type="ref"} However, this study did not include several of the Hispanic/Latino subpopulations and only included Mexican Hispanics. In addition, current cholesterol treatment guidelines were based on either non‐Hispanic white and/or black populations and did not take into account Hispanics/Latinos.

Hispanics/Latinos currently constitute 18% of the US population, making them the largest ethnic minority. It is important to study the statin eligibility to direct healthcare needs for primary prevention of cardiovascular disease in this ethnic group. The current guidelines provided an atherosclerotic cardiovascular disease (ASCVD) calculator to estimate 10‐year ASCVD risk. This calculator uses the same estimates for Hispanic/Latinos as that of whites. However, several of the Hispanics/Latinos share their ancestry with African ancestry, particularly Caribbean‐Hispanics (Cubans, Dominican, and Puerto Rican descent) and Central Americans.[4](#jah32144-bib-0004){ref-type="ref"}, [5](#jah32144-bib-0005){ref-type="ref"}, [6](#jah32144-bib-0006){ref-type="ref"}, [7](#jah32144-bib-0007){ref-type="ref"} It is likely that not recognizing the African ancestry in certain Hispanic groups could underestimate ASCVD risk. It is important to address these knowledge gaps as it would potentially provide data of public health importance that could be utilized to address the current disparities in primary prevention of ASCVD. Therefore, we determined the prevalence estimates from the Hispanic Community Health Study/Study of Latinos eligible for cholesterol treatment under the new 2013 ACC/AHA guidelines and previous NCEP/ATP III guidelines. We further examined the prevalence of US Hispanics/Latinos who are eligible for statin therapy but are currently not on statin therapy.

Methods {#jah32144-sec-0005}
=======

Study Design and Population {#jah32144-sec-0006}
---------------------------

The Hispanic community health study/study of Latinos (HCHS/SOL) is a community‐based study of 16 415 Hispanic/Latino adults aged 18 to 74 years at recruitment, recruited from 4 US metropolitan areas (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA).[8](#jah32144-bib-0008){ref-type="ref"} Participants were recruited by using a 2‐stage probability sample design, as described previously.[9](#jah32144-bib-0009){ref-type="ref"} A comprehensive battery of interviews relating to personal and family characteristics, health status and behaviors, and a clinical assessment with blood draws were conducted at an in‐person baseline clinic visit during 2008 to 2011. The study was approved by the institutional review boards at all participating institutions, and all participants gave written informed consent.

Risk Factor Assessment {#jah32144-sec-0007}
----------------------

Participants were asked to fast and refrain from smoking on the morning before the HCHS/SOL baseline clinic visit. Following a 5‐minute rest period, 3 seated blood pressure measurements were obtained with an automatic sphygmomanometer, which were averaged. Total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, and fasting glucose were measured using standardized methods described previously.[10](#jah32144-bib-0010){ref-type="ref"}, [11](#jah32144-bib-0011){ref-type="ref"} Height, waist circumference, and hip circumference were measured to the nearest centimeter and weight to the nearest 0.1 kg. BMI was calculated as weight in kilograms divided by height in meters squared. Interviewer‐administered questionnaires were used to collect information on age, sex, annual household income, educational attainment, Hispanic/Latino background, employment status, health insurance status, and history of smoking. Diabetes mellitus was defined as fasting glucose ≥126 mg/dL, 2‐hour--postload plasma glucose ≥200 mg/dL, hemoglobin A1c ≥6.5%, use of diabetes medications, or self‐reported history of diabetes mellitus. Participants were instructed to bring all prescription and nonprescription medications taken in the past 4 weeks; medication preparations, concentrations, and units were coded for analysis. We defined statin medication use as the use of at least 1 statin (3‐hydroxy‐3‐methyglutaryl coenzyme A reductase inhibitors) medication.

Cholesterol Treatment Guidelines and Statin Eligibility {#jah32144-sec-0008}
-------------------------------------------------------

Statin eligibility was defined by using the following NCEP/ATP III updated guidelines[12](#jah32144-bib-0012){ref-type="ref"} and ACC/AHA guidelines. As per 2004 NCEP/ATP III guidelines, statin‐eligible participants included participants with (1) prevalent coronary heart disease, defined as myocardial infarction, coronary bypass surgery, balloon angioplasty, or stent placement in coronary arteries, and low‐density lipoprotein (LDL) cholesterol of 100 or higher; (2) LDL cholesterol of 190 mg/dL or higher; (3) diabetes mellitus and LDL cholesterol of 100 or higher; (4) combination of calculated 10‐year coronary heart disease Risk (using the Framingham risk calculator) and LDL cholesterol levels: (1) risk of 20% or greater and LDL cholesterol of 100 mg/dL or higher; (2) risk of 10% to 20% and LDL cholesterol of 130 mg/dL or higher with 2 or more risk factors (smoking, hypertension, high‐density lipoprotein cholesterol less than 40 mg/dL, myocardial infarction or angina in first‐degree relative before age 50, and age \[45 years or older for men, 55 years or older for women\]); (3) risk of less than 10% and LDL cholesterol of 160 mg or higher with 2 or more risk factors.

By 2013 ACC/AHA class I guidelines,[13](#jah32144-bib-0013){ref-type="ref"} statin‐eligible participants included the following: (1) prevalent cardiovascular disease, defined as coronary heart disease, angina, or stroke; (2) LDL cholesterol of 190 mg/dL or higher; (3) diabetes mellitus and LDL cholesterol of 70 mg/dL or higher; and (4) 10‐year cardiovascular disease risk of 7.5% or greater, based on the pooled cohort equations and LDL cholesterol of 70 or higher.[14](#jah32144-bib-0014){ref-type="ref"}

Statistical Analysis {#jah32144-sec-0009}
--------------------

We chose a probability sampling strategy with face‐to‐face recruitment. Geographic clusters were stratified by the proportion of the population found to be Hispanic/Latino in the 2000 decennial census, and clusters in the "high concentration" stratum were selected at a higher rate than clusters in the "low concentration" stratum at the first stage of sample selection. An optimal delineation point between high and low concentration was determined for each field center using Cochran\'s cumulative √f rule.[15](#jah32144-bib-0015){ref-type="ref"} Furthermore, we also used Hispanic/Latino surnames to identify home addresses in these geographic areas and were oversamples compared to the home addresses without Hispanic/Latino surnames. We used SAS SURVEY command to calculate the prevalence estimates by using sampling weights, which took into account nonresponse and oversampling of specific population subgroups to provide weighted frequencies of descriptive variables and population estimates of statin‐therapy eligibility. Weights were calibrated to 2010 US census characteristics by age, sex, and Hispanic/Latino background in each field center\'s target population, in accordance with the procedures commonly used in population‐based studies.[9](#jah32144-bib-0009){ref-type="ref"} Continuous variables were compared using regression analysis and categorical variables were compared using Rao--Scott χ^2^ test. We also classified prevalence that were statin‐therapy eligible under previous versus newer guidelines. Under the new guidelines, statin eligibility falls into 3 criteria: (1) individuals with history of clinical cardiovascular disease; (2) those with LDL‐C ≥190 mg/dL; (3) those without known ASCVD with LDL‐C between 70 and 189 mg/dL but with ≥7.5% 10‐year ASCVD risk; and (4) those with diabetes mellitus and LDL‐C ≥70 mg/dL. The new Pooled Cohort Risk Assessment calculator was used to assess ASCVD risk using white estimates for Hispanics.[14](#jah32144-bib-0014){ref-type="ref"}

We then identified individuals who were not treated (undertreatment) by statin therapy but were classified as eligible for statin therapy. We defined statin‐therapy undertreatment as the prevalence eligible for statin therapy under cholesterol treatment guideline but were not on statin. We then examined prevalence of various subgroups that were statin eligible under current and previous guidelines to show disparities and characteristics of these individuals. Race factors into ASCVD risk prediction in the new ACC/AHA guidelines, with recommendations to assume white risk estimates in all Hispanics. Since certain Hispanic groups have more African ancestry, the current guidelines fail to consider the complexity of the Hispanic/Latino population. Thus, race was treated separately in sensitivity analysis. All analyses were weighted to adjust for sampling probability and nonresponse, to make the estimates applicable to the target population from which the HCHS/SOL sample was drawn in accordance with guidelines suggested by the HCHS/SOL Steering and Data Analysis Committee. A *P* value of \<0.05 was considered significant. All analyses were performed using SAS v. 9.3 (Cary, NC).

Results {#jah32144-sec-0010}
=======

Participant Characteristics {#jah32144-sec-0011}
---------------------------

Descriptive characteristics are shown in Table [1](#jah32144-tbl-0001){ref-type="table-wrap"}. Hispanics/Latinos statin‐therapy eligible by ACC/AHA guidelines were more often older, more males, and had higher systolic blood pressure and total cholesterol than participants eligible by NCEP/ATP III guidelines. On the other hand, the prevalence of obesity and antihypertensive medication use was lower for statin‐eligible participants by ACC/AHA guidelines than NCEP/ATP III guidelines.

###### 

Prevalence Estimates and 95% CI by Category of ATP III and ACC/AHA Cholesterol Guidelines for Participants in the HCHS/SOL

  Characteristic                    All Cohort          Statin Eligible by ATP III Guidelines   Statin Eligible by ACC/AHA Guidelines   Newly Eligible for Statin by ACC/AHA Guidelines
  --------------------------------- ------------------- --------------------------------------- --------------------------------------- -------------------------------------------------
  Age, y                            41.0 (0.3)          52.9 (0.4)                              54.3 (0.4)                              55.3 (0.5)
  Male                              47.9 (46.8, 48.9)   45.1 (42.6, 47.7)                       52.8 (50.8, 54.8)                       61.7 (58.7, 64.7)
  Females                           54.4 (51.1, 53.2)   54.8 (52.3, 57.4)                       47.2 (45.2, 49.2)                       38.3 (35.3, 41.4)
  Hypertension                      21.8 (20.6, 22.9)   51.7 (49.0, 54.2)                       50.9 (48.6, 53.3)                       48.7 (45.4, 52.0)
  Smoking status                                                                                                                        
  Never                             61.3 (60.0, 62.5)   56.2 (52.6, 58.7)                       49.2 (47.1, 51.3)                       40.9 (37.6, 44.1)
  Former                            17.4 (16.5, 18.2)   24.8 (22.6, 26.9)                       24.5 (22.7, 26.2)                       24.1 (21.3, 26.9)
  Current                           21.4 (20.3, 22.5)   19.1 (16.9, 21.3)                       26.3 (24.2, 28.4)                       35.0 (31.9, 38.2)
  Health insurance                  50.5 (48.7, 52.4)   59.4 (56.7, 62.2)                       59.9 (57.6, 62.2)                       59.6 (56.2, 63.0)
  Education                                                                                                                             
  Lower than high school            32.5 (31.1, 33.9)   43.5 (40.9, 46.0)                       42.6 (40.4, 44.7)                       40.8 (37.7, 43.9)
  High school or equivalent         28.4 (27.3, 29.5)   23.9 (21.6, 26.3)                       23.0 (21.2, 24.8)                       22.0 (19.4, 24.6)
  Higher than high school           39.1 (37.5, 40.7)   32.6 (30.0, 35.1)                       34.4 (32.2, 36.7)                       37.2 (34.0, 40.4)
  Income ≥\$40 000/y                20.4 (18.5, 22.4)   15.7 (13.3, 18.0)                       16.2 (14.3, 18.2)                       16.8 (14.0, 19.7)
  Mod/high physical activity        44.5 (43.2, 45.8)   32.5 (29.7, 35.3)                       35.3 (33.0, 37.6)                       38.9 (35.4, 42.2)
  Antihypertensive use              12.8 (12.0, 13.7)   39.4 (36.9, 42.0)                       33.1 (31.0, 35.2)                       25.8 (23.2, 28.4)
  Systolic blood pressure, mm Hg    119.9 (0.2)         128.0 (0.5)                             130.9 (0.4)                             133.0 (0.6)
  Obese (BMI ≥30 kg/m^2^)           39.6 (38.2, 40.9)   55.1 (52.7, 57.6)                       48.1 (46.1, 50.2)                       39.8 (36.6, 43.1)
  Total cholesterol, mg/dL          194.3 (0.6)         210.6 (1.4)                             214.6 (1.1)                             218.3 (1.6)
  High‐density lipoprotein, mg/dL   48.5 (0.2)          46.6 (0.3)                              47.2 (0.3)                              47.4 (0.4)
  Hispanic subgroups                                                                                                                    
  Dominican                         10.4 (8.9, 11.8)    14.4 (12.8, 16.0)                       23.3 (21.1, 25.5)                       11.9 (9.8, 12.2)
  Central American                  7.7 (6.6, 8.8)      14.6 (13.2, 16.0)                       23.5 (21.5, 25.6)                       10.8 (9.6, 12.1)
  Cuban                             20.9 (17.5, 24.3)   17.1 (15.1, 19.2)                       36.6 (32.7, 40.5)                       21.8 (19.5, 24.1)
  Mexican                           39.0 (35.6, 42.3)   15.2 (14.2, 16.2)                       22.3 (20.9, 23.7)                       9.7 (8.8, 10.5)
  Puerto Rican                      16.9 (15.2, 18.5)   18.8 (17.5, 20.1)                       31.6 (29.7, 33.5)                       15.3 (14.0, 16.5)
  South American                    5.2 (4.5, 5.8)      10.6 (9.3, 11.9)                        21.5 (19.5, 23.5)                       12.2 (10.8, 13.6)

Continuous variables are expressed as mean (standard error) and categorical as numbers (percentage). ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, 3rd National Cholesterol Education Program Adult Treatment Panel; HCHS/SOL, Hispanic Community Health Study/Study of Latinos.

John Wiley & Sons, Ltd

Application of 2013 ACC/AHA Cholesterol Treatment Guidelines to the Cohort {#jah32144-sec-0012}
--------------------------------------------------------------------------

[Figure](#jah32144-fig-0001){ref-type="fig"} shows the breakdown of study participants by cholesterol treatment guidelines. Out of 16 415 participants, 4160 (26.9%; 95% CI 25.7--28.0%) were statin eligible under the 2013 ACC/AHA guidelines while 2609 (15.9%; 95% CI 15.0--16.7%) were statin eligible under the NCEP/ATP III guidelines. This eligibility was based on prior history of ASCVD in 771 (4.7%; 95% CI 4.2--5.2%), LDL ≥190 mg/dL in 640 (3.9%; 95% CI 3.5--5.3%), history of diabetes mellitus in 2101 (12.8%; 95% CI 12.0--13.5%), and LDL ≥70 mg/dL with 10‐year ASCVD risk of ≥7.5% in 2281 (13.9%; 95% CI 13.0--14.7%) (Table [2](#jah32144-tbl-0002){ref-type="table-wrap"}). The overall most common indication for statin eligibility among all Hispanics/Latinos subgroups was having ASCVD risk of ≥7.5%. When stratified by age and sex, Puerto Rican females aged 18 to 64 years had the highest prevalence of statin‐eligible participants by 10‐year ASCVD risk of ≥7.5% criteria (χ^2^ statistic \<0.05) than other subgroups (Table S1).

![Eligibility for statin therapy. ACC/AHA indicates American College of Cardiology/American Heart Association; CVD, cardiovascular disease; DM, diabetes mellitus; LDL, low‐density lipoprotein; NCEP/ATP III, 3rd National Cholesterol Education Program Adult Treatment Panel; PCE, pooled cohort equation.](JAH3-6-e005045-g001){#jah32144-fig-0001}

###### 

Prevalence Estimates and 95% CI for Statin Therapy by 2013 ACC/AHA Cholesterol Treatment Class I Guideline‐Based Categories

                     History of ASCVD    *P* Value        LDL ≥190 mg/dL   *P* Value           Diabetes Mellitus   *P* Value   ≥7.5% of ASCVD Risk and LDL ≥70 mg/dL   *P* Value
  ------------------ ------------------- ---------------- ---------------- ------------------- ------------------- ----------- --------------------------------------- -----------
  All                4.7 (4.2, 5.2)                       3.9 (3.5, 4.3)                       12.8 (12.0, 13.5)               13.9 (13.0, 14.7)                       
  Age 18 to 44, y    2.4 (2.1, 2.7)      \<0.0001         2.2 (2.0, 2.5)                       5.0 (4.7, 5.4)      \<0.0001    1.5 (1.3, 1.7)                          \<0.0001
  Age 45 to 64, y    7.0 (6.4, 7.6)      6.7 (6.1, 7.3)   \<0.0001         20.7 (19.6, 21.7)   21.8 (20.6, 23.0)                                                       
  Age \>65, y        12.6 (11.2, 14.1)   5.2 (4.4, 6.1)                    37.4 (34.5, 40.4)   71.0 (66.3, 75.7)                                                       
  Female             2.0 (1.6, 2.3)      0.0001           2.0 (1.7, 2.2)   0.48                7.2 (6.6, 7.8)      0.008       5.6 (5.1, 6.1)                          \<0.0001
  Male               2.8 (2.3, 3.2)      1.9 (1.6 2.2)    5.6 (5.1, 6.0)   8.3 (7.6, 8.9)                                                                              
  Dominican          4.2 (3.6, 4.9)      \<0.0001         3.8 (3.2, 4.4)                       11.4 (10.1, 12.8)   \<0.0001    10.4 (9.0, 11.7)                        \<0.0001
  Central American   3.4 (2.7, 4.0)      4.0 (3.4, 4.7)                    11.6 (10.5, 12.8)   11.5 (10.4, 12.7)                                                       
  Cuban              5.3 (4.6, 6.1)      5.7 (5.0, 6.5)                    13.9 (12.2, 15.6)   23.6 (21.2, 26.1)                                                       
  Mexican            3.4 (3.0, 3.9)      3.4 (3.0, 3.9)   0.0002           11.9 (11.1, 12.7)   9.7 (8.9, 10.4)                                                         
  Puerto Rican       7.5 (6.7, 8.3)      3.1 (2.6, 3.6)                    15.8 (14.7, 16.9)   16.9 (15.5, 18.2)                                                       
  South American     3.5 (2.8, 4.2)      4.2 (3.4, 4.9)                    8.3 (7.2, 9.4)      12.3 (10.8, 13.7)                                                       

The percentages are related to the total number of individuals eligible for statin therapy by ACC/AHA class I guidelines in each subgroup. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; LDL, low‐density lipoprotein.

John Wiley & Sons, Ltd

Increase in Eligibility for Statin Therapy {#jah32144-sec-0013}
------------------------------------------

There was an increase in eligibility for statin therapy under the ACC/AHA guidelines across all Hispanic/Latino subgroups as shown in Table [3](#jah32144-tbl-0003){ref-type="table-wrap"}. The increase in eligibility was mainly driven by ASCVD risk score. There was an absolute increase by 11.0% (69.1% relative increase). Particularly, the subgroups aged \>65 years and males had the highest increase in statin eligibility under the ACC/AHA guidelines: an absolute increase by 45.6% (114.9% relative increase) and 14.7% (98.6% relative increase), respectively. Among the Hispanic/Latino subgroups, in unadjusted analysis, Cubans and South Americans had the highest increase in statin eligibility (Table [3](#jah32144-tbl-0003){ref-type="table-wrap"}). The increase in eligibility was more pronounced in \>65‐year‐old individuals and males (*P*\<0.05). The age‐ and sex‐stratified analyses shown in Table S2 also demonstrated a consistent pattern of increase in prevalence of statin therapy among statin‐eligible participants. In age‐ and sex‐adjusted analyses, the South American subgroup had the least prevalence of statin‐eligible participants by both NCEP/ATP III guidelines and ACC/AHA guidelines, while the Puerto Rican subgroup had the highest prevalence of statin‐eligible participants by both guidelines (Table S3).

###### 

Prevalence Estimates and 95% CI of Statin‐Therapy Eligible Under Both Guidelines

                     2004 ATP III/NCEP   2013 ACC/AHA        Newly Eligible      *P* Value   Absolute Increase[a](#jah32144-note-0005){ref-type="fn"}   Relative Increase[b](#jah32144-note-0006){ref-type="fn"}
  ------------------ ------------------- ------------------- ------------------- ----------- ---------------------------------------------------------- ----------------------------------------------------------
  All                15.9 (15.0, 16.7)   26.9 (25.7, 28.0)   13.2 (12.4, 14.1)               11.0%                                                      69.1%
  Age 18 to 44, y    7.0 (6.7, 7.2)      10.0 (9.4, 10.5)    4.3 (3.9, 4.6)      \<0.0001    3.0%                                                       42.8%
  Age 45 to 64, y    25.4 (24.5, 26.3)   42.0 (39.8, 44.1)   20.4 (19.1, 21.7)   16.6%       65.3%                                                      
  Age \>65, y        43.4 (38.8, 47.9)   89.0 (83.5, 94.5)   49.9 (46.3, 53.4)   45.6%       114.9%                                                     
  Female             16.8 (15.9, 17.7)   24.4 (23.3, 25.6)   9.7 (9.1, 10.3)     \<0.0001    7.6%                                                       45.2%
  Male               14.9 (14.1, 15.7)   29.6 (28.1, 31.1)   17.8 (16.7, 18.8)   14.7%       98.6%                                                      
  Dominican          14.4 (12.8, 16.0)   23.4 (21.2, 25.5)   11.0 (9.8, 12.2)    \<0.0001    9.0%                                                       62.5%
  Central American   14.6 (6.9, 22.4)    23.6 (21.5, 25.6)   10.8 (9.6, 12.1)    9.0%        61.6%                                                      
  Cuban              17.1 (15.1, 19.2)   36.6 (32.7, 40.5)   21.8 (19.5, 24.1)   19.5%       114.0%                                                     
  Mexican            15.2 (14.2, 16.2)   22.3 (20.9, 23.7)   9.7 (8.8, 10.5)     7.1%        46.7%                                                      
  Puerto Rican       18.8 (17.5, 20.1)   31.6 (29.7, 33.5)   15.3 (14.0, 16.5)   12.8%       68.1%                                                      
  South American     10.6 (9.3, 11.9)    21.5 (19.5, 23.5)   12.2 (10.8, 13.6)   10.9%       102.8%                                                     

ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III/NCEP, 3rd National Cholesterol Education Program Adult Treatment Panel.

Absolute increase in eligibility in a subgroup=(\[Eligible by ACC/AHA−Eligible by ATP III/NCEP\]/total number at risk in that subgroup)×100%.

Relative increase in eligibility in a subgroup=(\[Eligible by ACC/AHA−Eligible by ATP III/NCEP\]/Eligible by ATPIII/NCEP)×100%.

John Wiley & Sons, Ltd

Statin Treatment Rates of Hispanics/Latinos Under 2013 ACC/AHA and 2004 NCEP/ATP III Guidelines {#jah32144-sec-0014}
-----------------------------------------------------------------------------------------------

Among Hispanics/Latinos, prevalence of statin use was 7.9% (95% CI 7.2--8.6%). Of the participants who were statin eligible, only about one third and one fifth of the participants were taking statins under NCEP/ATP III guidelines (28.2% \[95% CI 26.3--30.0%\]) and ACC/AHA guidelines (20.6% \[95% CI 19.4--21.9%\]), respectively (*P* for difference \<0.0001). Figure S1 shows prevalence of statin therapy for age, sex, and Hispanic/Latino subgroups under both treatment guidelines. This figure shows that younger participants, males, and all Hispanic/Latino subgroups except Puerto Ricans were undertreated by statins. We observed that among those who were statin eligible under the ACC/AHA guidelines, those not on statin therapy were significantly younger and more likely to be males, smokers, and hypertensives. They were also more likely to have no medical insurance and be lower income (Table [4](#jah32144-tbl-0004){ref-type="table-wrap"}).

###### 

Prevalence Estimates (%) and 95% CI for Statin Eligible on Statins and Not on Statins Under Both Guidelines

  Variables                         Statin Eligible by ATP III Guidelines on Statins   Statin Eligible by ATP III Guidelines Not on Statins   *P* Value           Statin Eligible by ACC/AHA Guidelines on Statins   Statin Eligible by ACC/AHA Guidelines Not on Statins   *P* Value
  --------------------------------- -------------------------------------------------- ------------------------------------------------------ ------------------- -------------------------------------------------- ------------------------------------------------------ -----------
  All                               28.2 (26.3, 30.0)                                  71.8 (68.4, 75.3)                                                          20.6 (19.4, 21.9)                                  79.4 (75.6, 83.1)                                      
  Age, y                            59.8 (0.5)                                         50.5 (0.5)                                             \<0.001             61.0 (0.4)                                         52.7 (0.4)                                             \<0.001
  Male                              43.4 (38.3, 48.4)                                  45.2 (42.1, 48.3)                                      0.29                46.9 (42.3, 51.4)                                  54.0 (51.6, 56.2)                                      0.007
  Female                            56.6 (51.5, 61.6)                                  54.9 (51.8, 58.0)                                      53.1 (48.6, 57.7)   46.0 (43.7, 48.3)                                                                                         
  Hypertension                      77.9 (74.1, 81.7)                                  42.8 (39.7, 45.9)                                      \<0.001             75.7 (71.9, 79.4)                                  45.6 (42.8, 48.4)                                      \<0.001
  Smoking status                                                                                                                              0.03                                                                                                                          \<0.001
  Never                             55.9 (51.5, 60.4)                                  56.4 (53.2, 59.6)                                                          53.2 (49.2, 57.3)                                  48.5 (46.0, 50.9)                                      
  Former                            28.8 (24.7, 32.8)                                  23.6 (21.1, 26.0)                                                          30.1 (26.3, 33.9)                                  23.1 (21.1, 25.1)                                      
  Current                           15.3 (11.8, 18.9)                                  20.0 (17.5, 22.5)                                                          16.7 (13.3, 20.1)                                  28.4 (26.1, 30.8)                                      
  Health insurance                  82.3 (78.4, 86.2)                                  50.9 (47.9, 53.8)                                      \<0.001             85.6 (82.6, 88.6)                                  53.4 (50.9, 56.0)                                      \<0.001
  Education                                                                                                                                   0.007                                                                                                                         0.004
  Lower than high school            14.4 (12.7, 16.1)                                  29.6 (27.1, 32.1)                                                          49.6 (45.4, 53.7)                                  41.1 (38.6, 43.5)                                      
  High school or equivalent         5.4 (4.0, 6.8)                                     17.6 (15.5, 19.7)                                                          18.4 (14.8, 21.9)                                  23.6 (21.5, 25.8)                                      
  Higher than high school           8.4 (6.9, 10.0)                                    24.4 (22.2, 26.7)                                                          32.0 (27.4, 36.7)                                  35.3 (32.8, 37.7)                                      
  Income ≥\$40 000/y                15.8 (11.6, 20.1)                                  15.1 (12.6, 17.5)                                      0.02                18.2 (14.0, 22.4)                                  15.7 (13.7, 17.8)                                      0.09
  Moderate/high physical activity   27.9 (22.4, 33.5)                                  33.6 (30.2, 36.8)                                      0.10                26.8 (22.1, 31.6)                                  63.0 (60.2, 65.8)                                      0.001
  Antihypertensive use              70.5 (66.4, 74.6)                                  27.3 (24.7, 29.8)                                      \<0.001             65.7 (61.6, 69.8)                                  24.6 (22.5, 26.7)                                      \<0.001
  Systolic blood pressure, mm Hg    131.2 (0.8)                                        126.7 (0.6)                                            \<0.001             133.1 (0.7)                                        130.4 (0.5)                                            \<0.001
  Obese (BMI ≥30 kg/m^2^)           16.4 (14.3, 18.5)                                  39.2 (36.7, 41.6)                                      0.14                10.6 (9.2, 12.1)                                   37.6 (35.6, 39.7)                                      0.10
  Total cholesterol, mg/dL          185.0 (2.1)                                        220.3 (1.6)                                            \<0.001             193.5 (1.9)                                        220.3 (1.2)                                            \<0.001
  High‐density lipoprotein, mg/dL   47.6 (0.6)                                         46.3 (0.4)                                             \<0.001             48.5 (0.6)                                         46.8 (0.3)                                             \<0.001
  Hispanic subgroups                                                                                                                          \<0.001                                                                                                                       
  Dominican                         10.5 (7.6, 13.3)                                   9.2 (7.0, 11.3)                                                            9.8 (7.3, 12.3)                                    8.7 (7.0, 10.3)                                        
  Central American                  5.7 (3.7, 7.8)                                     7.8 (6.4, 9.3)                                                             4.9 (3.3, 6.6)                                     7.2 (6.0, 8.5)                                         
  Cuban                             23.8 (18.4, 29.1)                                  22.3 (18.0, 26.7)                                                          26.2 (21.6, 30.7)                                  29.2 (24.6, 33.7)                                      
  Mexican                           29.4 (24.5, 34.2)                                  40.7 (36.3, 45.0)                                                          28.0 (23.7, 32.3)                                  33.2 (29.3, 37.2)                                      
  Puerto Rican                      27.3 (23.3, 31.3)                                  27.3 (23.3, 31.3)                                                          27.6 (23.9, 31.2)                                  17.3 (15.0, 19.7)                                      
  South American                    3.3 (2.1, 4.5)                                     3.7 (2.7, 4.7)                                                             3.6 (2.4, 4.7)                                     4.4 (3.5, 5.2)                                         

ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III/NCEP, 3rd National Cholesterol Education Program Adult Treatment Panel.

Continuous variables are expressed as mean (SE) and categorical as numbers (percentage). Continuous variables were compared using survey regression method and categorical variables were compared using Rao--Scott χ^2^ method.
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Accounting for African Ancestry of Dominicans, Puerto Ricans, Dominicans, and Central Americans for Calculation of 10‐Year ASCVD Risk {#jah32144-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------------

When we used the white coefficient to calculate 10‐year ASCVD risk for all Hispanics/Latinos subgroups, about one fourth of the participants were statin eligible (26.9% \[95% CI 25.8--28.0%\]) under ACC/AHA guidelines. When we used black coefficient to estimate ASCVD risk for Dominicans, Puerto Ricans, and Central Americans, 28.2% (95% CI 27.0--29.4%) were statin eligible, which was a 1.3% absolute increase in statin eligibility while 0.40% (95% CI 0.29--0.53%) became ineligible.

Discussion {#jah32144-sec-0016}
==========

In this large population‐based sample of Hispanics/Latinos living in the United States, we observed that a higher number of Hispanics/Latinos will be eligible for statin therapy under the new 2013 ACC/AHA guidelines. The increase in eligibility was found across several demographic subgroups but was particularly higher among males, middle aged (45--64 years) individuals, and among certain Hispanic background groups (Dominicans, Puerto Ricans, and Central Americans). We also found that only one third and one fifth of statin‐eligible Hispanics/Latinos under NCEP/ATP III guidelines and 2013 ACC/AHA guidelines, respectively, were taking statins. In addition, we found that changing the estimates for 10‐year ASCVD risk for the Hispanic/Latino subgroups for Dominicans, Puerto Ricans, and Central Americans did not significantly increase statin eligibility.

To our knowledge, this is the first population‐based study of Hispanics/Latinos living in the United States that has provided prevalence estimates of statin eligibility under 2013 ACC/AHA cholesterol and 2004 NCEP/ATP III cholesterol treatment guidelines. The findings of this study are consistent with other studies showing increase in statin eligibility among whites,[16](#jah32144-bib-0016){ref-type="ref"} Europeans,[17](#jah32144-bib-0017){ref-type="ref"} and Koreans, Mexican majority Hispanics, and Chileans.[18](#jah32144-bib-0018){ref-type="ref"}, [19](#jah32144-bib-0019){ref-type="ref"}, [20](#jah32144-bib-0020){ref-type="ref"}, [21](#jah32144-bib-0021){ref-type="ref"} The newer guidelines have expanded the indications for statin therapy by including ASCVD risk score and have shown almost doubling of the statin eligibility.[16](#jah32144-bib-0016){ref-type="ref"}, [17](#jah32144-bib-0017){ref-type="ref"}, [18](#jah32144-bib-0018){ref-type="ref"}, [22](#jah32144-bib-0022){ref-type="ref"} Our study confirms a prior study where the majority of the Hispanics were of Mexican origin. However, the study did not provide prevalence estimates and did not represent all the subgroups of Hispanic/Latino origin.[22](#jah32144-bib-0022){ref-type="ref"} An important aspect of our analysis that sets it apart from other analyses is inclusion of younger (\<45‐year‐old) individuals who are included in the guidelines but have not been studied in the European cohort. Approximately one tenth of these individuals were eligible for statins under the new guidelines and had significant differences among the various Hispanic subgroups, with the Puerto Rican female subgroup having the highest prevalence of individuals who qualified for statin therapy. The prevalence of statin therapy eligibility among 6 Hispanics/Latinos subgroups that this study has provided has not been previously studied. In addition, there was a concern that using white estimates for Hispanics/Latinos under the newer guidelines might not be appropriate for Hispanic subgroups with predominance of African ancestry. However, we did not detect a significant difference in increase in prevalence when white estimates were used for Dominicans, Puerto Ricans, Central Americans, and Cubans.

Furthermore, the ASCVD risk estimator under the current guidelines may not hold for Hispanics the same way as they do for other ethnicities. The current guidelines rely on cardiovascular risk factors to assign particular 10‐year ASCVD risk. Hispanics are known to have a higher burden of cardiovascular risk factors and thus are likely to have higher estimates for ASCVD risk based on current guidelines; however, there is a documented notion that despite high cardiovascular risk factor burden, Hispanics suffer from much lower overall and cardiovascular mortality than other race--ethnic groups such as non‐Hispanic whites and black Americans, a phenomenon known as "Hispanic paradox" in scientific literature.[23](#jah32144-bib-0023){ref-type="ref"}, [24](#jah32144-bib-0024){ref-type="ref"} The Hispanic paradox may or may not be applicable across all Hispanic background groups,[25](#jah32144-bib-0025){ref-type="ref"}, [26](#jah32144-bib-0026){ref-type="ref"} and future prospective data from the HCHS/SOL will help elucidate cardiovascular risk for Hispanics. This becomes important in the light of a recent "real‐world" study that showed that ASCVD risk by AHA/ACC guidelines might lead to overestimation of ASCVD risk.[27](#jah32144-bib-0027){ref-type="ref"} Among 18 745 (6.1%) Hispanics included in this study, the risk score overestimated the risk of ASCVD events. Thus, our study further emphasizes the critical need to have race/ethnic--based calibrated scores.[28](#jah32144-bib-0028){ref-type="ref"}

There are several implications of this study. First, this study demonstrates and confirms findings similar to other cohort studies in Hispanics. Secondly, it showed important differences across several subgroups of Hispanics/Latinos. Thirdly, the study showed gross undertreatment of US‐based Hispanics/Latinos in regard to primary prevention of cardiovascular disease. This level of undertreatment is likely to increase when the indications for statin therapy are going to increase eligible participants under the newer ACC/AHA cholesterol treatment guidelines. We also observed gross differences in demographics of participants already on statin therapy compared with those not on statin therapy but who were eligible under the new and old guidelines. These differences will potentially inform public health policy makers to target certain subgroups of Hispanics/Latinos to improve primary prevention of ASCVD. Lastly, the study did not show a significant increase in statin eligibility when black ASCVD risk estimates were used to identify participants with greater than 7.5% 10‐year risk of ASCVD, suggesting that it may be appropriate to use any of the estimates; however, having in mind the Hispanic paradox, the white and black estimates might erroneously increase the statin eligibility in Hispanics/Latinos. Hispanics/Latinos constitute the largest ethnic minority in the United States and already suffer from disparities in cholesterol treatment that could potentially be increased by inaccurately estimating their ASCVD risk. However, this does not disregard the need for clinician--patient risk discussion. We also identified 2% to 3% of Hispanics who became ineligible by ACC/AHA guidelines who were eligible under NCEP/ATP III guidelines. This is an important group to focus on, as they might still be at high risk of cardiovascular disease and would benefit from clinician--patient risk discussion.

There are several limitations of this analysis. First, this is a cross‐sectional analysis and does not take into account the longitudinal changes in the risk factors that determine the eligibility of statin use nor the pretreatment LDL cholesterol levels among individuals who were using statins at enrollment. Therefore, it is likely that some individuals might be misclassified. Second, much of the data were self‐reported, which can be a source of recall bias. However, the risk scores were calculated based on objective data. Third, we did not account for treatment adherence, which in several series has been reported to be low for statins.[29](#jah32144-bib-0029){ref-type="ref"}, [30](#jah32144-bib-0030){ref-type="ref"}, [31](#jah32144-bib-0031){ref-type="ref"}, [32](#jah32144-bib-0032){ref-type="ref"}

Currently, more than one third of the US community‐dwelling Hispanics/Latinos eligible under the new as well as old treatment guidelines are not on statin therapy. There is a need for Hispanics/Latinos--specific ethnic estimates for estimating 10‐year ASCVD risk. The study indicates the need for additional resources for improving cardiovascular health for Hispanics/Latinos.

Sources of Funding {#jah32144-sec-0017}
==================

The baseline examination of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was conducted as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01‐HC65233), University of Miami (N01‐HC65234), Albert Einstein College of Medicine (N01‐HC65235), Northwestern University (N01‐HC65236), and San Diego State University (N01‐HC65237). The following Institutes/Centers/Offices contributed to the HCHS/SOL first funding period through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, the National Institute of Deafness and Other Communications Disorders, the National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and the NIH Office of Dietary Supplements.
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**Table S1.** Age‐ and Sex‐Stratified Prevalence Estimates and 95% CI for Statin Therapy by 2013 ACC/AHA Cholesterol Treatment Class I Guideline‐Based Categories

**Table S2.** Age‐ and Sex‐Stratified Prevalence Estimates and 95% CI for Statin Therapy by NCEP/ATP III and 2013 ACC/AHA Cholesterol Treatment Guidelines

**Table S3.** Age‐ and Sex‐Adjusted Prevalence Estimates and 95% CI for Statin Therapy by NCEP/ATP III and 2013 ACC/AHA Cholesterol Treatment Guidelines

**Figure S1.** Prevalence (%) and 95% CI of eligible Hispanics/Latinos who are treated with statin therapy under each guideline.
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